
Opinion|Videos|July 29, 2024
Melanoma Research Beyond ASCO 2024: Upcoming Advances and Insights
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the current challenges in translating clinical trial results into real-world practice for melanoma treatment? How can this process be streamlined?
- Please discuss any other data in melanoma released at ASCO 2024 that you find noteworthy to share with colleagues. (Please be prepared to discuss during the interview)
- Outside of ASCO 2024, what ongoing research efforts are you most excited for in the treatment and management of melanoma? What can we look forward to through the end of the year and beyond?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

Obinutuzumab (Gazyva) led to complete remission of proteinuria in more patients than tacrolimus did, according to the FDA.

Infectious disease and urology clinicians described unclear treatment goals, infusion limits, and access barriers for newer UTI agents.

New ACACIA-HCM analyses at HCMS 2026 add imaging and quality-of-life data as Cytokinetics readies an FDA filing in nonobstructive HCM.

An oral SERD plus everolimus cut the risk of progression or death by 62% in ESR1-mutated advanced breast cancer.

New York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.

Phase 3 OASIZ-301 data at ACR 2026 show dazodalibep lowered systemic activity in Sjögren disease, with dryness gains at the every-4-weeks dose.
Advertisement
Advertisement
Trending on AJMC
1
Emerging Threats to Cell and Gene Therapy Access
2
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
3
FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer
4
FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMR
5

